A dermatology site can have an experienced investigator and a credible psoriasis patient population, yet still struggle when the protocol requires repeated biopsies, standardized skin assessments and visits that take longer than routine appointments. For sponsors and CROs, the issue is whether those requirements can be delivered reliably at the proposed location.
Plaque psoriasis trials vary. Some focus on clinician-rated disease response, while others add tissue collection, photographs, treatment washouts or lengthy observation. The right feasibility conversation therefore starts with a procedure-by-procedure review. It should establish which tasks are required, who owns each step, where they take place and how participants will be supported.
Start with the protocol, not the diagnosis list
A psoriasis diagnosis in a medical record does not establish eligibility. Depending on the study, the investigator may need to confirm plaque type, affected body surface area, current severity, prior systemic or biologic treatments, treatment response and washout timing. Records can help identify candidates, but the full protocol determines whether a person can be screened and randomized.
Sponsors should ask the site to separate documented information from details that require a fresh examination or referring-clinician confirmation. A patient willing to consider a study may not qualify after a baseline score, laboratory result or treatment-history review. A useful forecast acknowledges those uncertainties instead of treating every record as an available participant.
Site capacity also needs a study-specific assessment. A clinic providing routine dermatology care may have suitable patients, but must identify protected research appointment time, qualified staff and backup coverage for demanding visits.
Confirm assessment quality before the first baseline visit
Psoriasis protocols often rely on the Psoriasis Area and Severity Index (PASI) and physician global assessments, sometimes alongside body surface area, lesion assessments, photographs or patient-reported outcomes. These instruments are not interchangeable. For example, PASI reflects disease extent and severity, while a global assessment captures an overall clinician-rated category. The exact measures and thresholds belong to the current protocol.
Feasibility should name the assessors, required qualification or training, the planned scoring order and the backup if an assessor becomes unavailable. If photographs are required, confirm the lighting, background, anatomical views, image naming, privacy rules and approved upload process. Avoid assuming that a specialty clinic already possesses a sponsor-specific camera, rating certification or imaging platform.
The site should also explain how it will avoid inconsistent scoring when an assessment and biopsy are scheduled during the same visit. Who evaluates the skin first, what happens if a lesion becomes unsuitable, and how are deviations escalated? The answers should be documented before activation, not improvised on the day of a procedure.
Treat each biopsy as a separate operational workstream
A protocol requiring one skin biopsy is different from one requiring multiple samples at specified visits or from designated lesions. The sponsor needs to define the biopsy purpose, required versus optional status, collection method, anatomical location, clinical risk criteria, specimen volume or dimensions, and whether repeat sampling is allowed. A capable site can then confirm personnel, sterile supplies, anesthetic requirements if applicable, post-procedure instructions and emergency escalation.
FDA and the HHS Office for Human Research Protections issued draft guidance in January 2025 on research tissue biopsies. It distinguishes biopsies required for participation from optional research biopsies and emphasizes justification, risk assessment and informed consent. That document remains draft guidance, not a new binding biopsy rule. The approved protocol, IRB documents and applicable regulations govern the actual study.
Consent is a process rather than a signature collected just before sampling. Candidates should have time to ask about discomfort, potential bleeding or infection, scarring, wound care and any consequences of declining an optional versus required biopsy. The team should never promise a painless procedure or suggest that medical care depends on agreeing to research. Any biopsy performed for research needs appropriate consent before it happens.
Trace the specimen from the room to the receiving laboratory
A skilled dermatologist does not by itself complete the specimen pathway. Ask where a specimen will be labeled, whether it is placed in fixative or a sponsor-supplied medium, what temperatures apply, who completes requisitions and who verifies collection and shipment time points. If the protocol requires immediate processing, same-day courier pickup or a central laboratory kit, each dependency needs an owner and a backup.
Sponsors should distinguish on-site procedure capability from coordinated outside laboratory access. The proposed location may have adequate private exam space while depending on a named pathology or specialty laboratory for processing. Both arrangements can be workable when they are documented, approved for the study and tested against visit windows. Shipping routes and specimens should be checked for weekends and holidays as well as ordinary weekdays.
A practical readiness test follows one specimen from participant identification to final chain-of-custody record. Confirm training, labeling conventions, transport, temperature monitoring when required, deviations and incident reporting. The test may uncover a missing vendor document or pickup cutoff before the first participant is scheduled.
Explain the full visit burden to candidates
A procedure-heavy psoriasis visit may combine questionnaires, physician scoring, photography, sample collection, investigational-product activities, laboratory checks and post-biopsy observation. Sponsors should ask for a visit-by-visit time estimate instead of relying on a standard office appointment length. Also check recovery instructions, work or childcare commitments, transportation needs and the logistics of follow-up assessments.
A prospective participant may be comfortable with study medication but concerned about biopsy discomfort or the visibility of a sampling site. The research team should explain what happens, how questions are answered, what follow-up is available and what scheduling flexibility the protocol genuinely permits. That discussion is part of ethical recruitment and a realistic retention plan, not an argument to minimize risk.
For repeated procedure visits, ask what happens if a participant has a flare, a change in treatment, an intercurrent illness or a missed appointment. The investigator makes medical and eligibility decisions; the coordinator manages approved communication and scheduling. Any unscheduled procedures or follow-up should follow the protocol and clinical judgment.
Use WCR's published psoriasis case with clear limits
Wellness Clinical Research published a phase 1a/b plaque psoriasis case study involving restrictive eligibility and required biopsies. In that specific study, 15 participants were screened in less than two months, with one screen failure and one early withdrawal reported as separate outcomes. The research team described explaining biopsy requirements and addressing concerns about discomfort before participants committed.
The case study states that an experienced dermatologist performed required biopsies, and that all but one randomized participant remained in follow-up as the study neared completion. This was an interim retention observation, not a final completion rate. These results should not be applied as expected recruitment or retention numbers for another site, protocol or sponsor.
What the example does show is an operational approach: a procedure was treated as both a clinical requirement and a participant decision. WCR publicly describes its dermatology research capabilities, including private examination rooms and coordinated specialty access across its research network. Sponsors should still confirm which investigator, location, procedure resources and external partners are available for their specific study.
A practical psoriasis site-selection checklist
Use an evidence-based walkthrough before awarding a site. Ask for named owners and supporting documents instead of broad statements about readiness. Any gap should have a resolution plan and a realistic date.
- Population: Which protocol criteria can be checked in records, and which require current PASI, global assessments, treatment history or screening tests?
- Investigator: Who will conduct medical reviews and biopsies? Is specialty coverage documented for the proposed location and visit windows?
- Assessment consistency: Who performs scoring and photography, how are they trained, and who covers missed or rescheduled visits?
- Biopsy readiness: Which samples are required or optional, where are they taken, and how will risks and consent be explained?
- Specimen path: What supplies, processing, labeling, courier windows, chain-of-custody steps and laboratory confirmations are required?
- Participant experience: What are realistic visit lengths, wound-care instructions, transportation needs and support arrangements?
- Oversight: How will procedure complications, missed samples, protocol deviations and follow-up questions reach the investigator promptly?
Make the selection decision on capability, not optimism
An appropriate psoriasis research site links three forms of evidence: credible clinical screening, reproducible dermatology assessments and reliable procedure logistics. A sponsor should review those independently. An investigator's track record cannot substitute for a missing specimen route, and equipment cannot solve a schedule that participants cannot reasonably keep.
For WCR opportunities, the Miami Lakes and Puerto Rico teams can discuss investigator fit, research staffing, assessment requirements and whether any outside service can support the proposed protocol. Available arrangements must be verified for each location rather than assumed from the network's therapeutic experience. Sponsors and CROs can submit a study opportunity to begin that protocol-specific review.
Related WCR capabilities
Sources and further reading
- Plaque psoriasis phase 1a/b case study
- Dermatology clinical research capabilities
- Considerations for Including Tissue Biopsies in Clinical Trials (Draft, January 2025)
- Protection of Human Subjects; Informed Consent (21 CFR Part 50)
- ICH E6(R3) Good Clinical Practice, Principles and Annex 1
- An Oral Interleukin-23 Receptor Antagonist Peptide for Plaque Psoriasis
